|
China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI),which develops, manufactures, and markets specialty pharmaceuticalproducts in China, today announced the completion of clinicaltrials of the cholesterol-lowering drug, rosuvastatin (genericversion of Crestor ), which the Company intends to commercialize in the large andexpanding Chinese healthcare market. Rosuvastatin helps reduce low-density lipoprotein cholesterol (LDL-C, or "bad cholesterol") and raise high-density lipoproteincholesterol (HDL-C, or "good cholesterol"). In the Company'sclinical trials, rosuvastatin demonstrated better effect inlowering LDL-C compared to control groups using atorvastatin(Lipitor). A 10 mg dose of rosuvastatin lowered LDL-C by 45% andhelped 82% of all subjects reach LDL-C treatment target levels. According to Chinese State Food and Drug Administration (SFDA)information center, the market size for cholesterol-lowering drugsin China reached RMB 7.9 billion (approximately USD$1.1 billion) in2008, and more than RMB 9.0 billion (approximately USD $1.3billion) in 2009. Rising disposable income among Chinese consumershas coincided with unhealthy changes in lifestyle and eatinghabits, leading to a growing incidence of obesity and high cholesterol in the country. Rosuvastatin (genericCrestor) is a prescription drug belonging to a group of medicinescalled statins, which are frontline drugs used to treat highcholesterol. Due to its significant position amongcholesterol-lowering drugs, rosuvastatin has been listed in the2009 National Insurance Catalogue (NIC) in China. Sales of Crestor reached USD$4.5 billion(1) globally in 2009. TheU.S. Food and Drug Administration (FDA) recently approved Crestor(rosuvastatin) to be prescribed for reducing the risk of heart attack and stroke in people without known heart disease but with increased risk of the getting the disease. The USapproval could be a harbinger of similar, expanded indications forrosuvastatin in China, which would add to the Company's marketopportunity. The Company is actively preparing to enter the SFDA productionapproval process, and will update shareholders when finalmilestones have been met to allow China Pharma to commercializethis exciting global product in China. The Company believes thisproduct will be one of the first versions of generic Crestor on theChinese market and expects it to contribute meaningfully to theCompany's overall revenues over the next few years, beginning in2011. China Pharma's CEO and President, Ms. Zhilin Li, commented, "We arethrilled to announce the completion of clinical trials of thecholesterol-lowering drug rosuvastatin. Rosuvastatin is safer andhas fewer liver related side-effects compared to other statins, animportant advantage given China's high incidence rate of liverdisease, which impacts approximately 20% of the population. We lookforward to introducing this advanced product to improve the livesof hyperlipidemia patients throughout China." Source: China Pharma Holdings, Inc. The e-commerce company in China offers quality products such as Glass Liquor Decanter Manufacturer , Decorative Glass Plates Manufacturer, and more. For more , please visit Drinking Glass Cup today!
Related Articles -
Glass Liquor Decanter Manufacturer, Decorative Glass Plates Manufacturer,
|
